Drugs

Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer

Photo taken from Matthew Goetz/LinkedIn

Apr 29, 2024, 14:18

Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer

Matthew Goetz, Professor of Oncology and Pharmacology at Mayo Clinic, shared on LinkedIn:

“An important question in the adjuvant treatment of high risk ER+/HER2 negative breast cancer with Abemacicib:

Is the benefit of Abemacicib compromised in those that require dose reductions?

A secondary analysis of MonarchE suggests that reducing the dose to manage side effects did not alter efficacy.

Clinicians should utilize dose modifications when necessary to maximize adherence.”

Matthew Goetz

Additional information.
Source: Matthew Goetz/LinkedIn

Abemacicib Ashwin Shahir Breast Cancer cancer Hope S. Rugo Irfan Cicin Jens Huober Joyce O'Shaughnessy Laura Testa Matthew Goetz Mayo Clinic Miguel Martin monarchE Nadia Harbeck OncoDaily Oncology Priya Rastogi Ran Wei Sara M. Tolaney Stephen R. D. Johnston Valentina Guarneri Valérie André

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity